Physician profile
Morris Levin
NPI 1538117403
$26,184.97
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,451 · 2020: $4,549 · 2021: $5,950 · 2022: $1,331 · 2023: $975 · 2024: $9,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,563 · Consulting Fee: $4,175 · Food and Beverage: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,562.50 |
| Consulting Fee | $4,175.00 |
| Food and Beverage | $166.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $6,593.26 | 2022-2024 | Emgality |
| Biodelivery Sciences International, INC. | $3,000.00 | 2021 | |
| Amneal Pharmaceuticals LLC | $2,950.00 | 2024 | |
| Supernus Pharmaceuticals, INC. | $2,842.03 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $2,624.75 | 2021 | |
| Upsher-Smith Laboratories LLC | $2,398.03 | 2020 | |
| Abbvie INC. | $2,334.46 | 2022-2024 | |
| Currax Pharmaceuticals LLC | $2,150.81 | 2020 | |
| Allergan, INC. | $1,137.50 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $121.81 | 2019 | |
| Lundbeck LLC | $32.32 | 2024 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.